title: The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes.
abstract: Fluoroquinolone antibiotics cause rare, but clinically important, adverse events including hyperglycaemia and hypoglycaemia. The present study focuses on the possible effect of levofloxacin and moxifloxacin on the cardiovascular functions of rats with type I diabetes. Both antibiotics caused bradycardia. Levofloxacin but not moxifloxacin caused hypoglycaemia in diabetic rats and an increase in amplitude of the ST segment revealed by electrocardiogram (ECG) analysis of isolated hearts. In pressurized mesenteric arteries, levofloxacin did not affect the endothelium-derived hyperpolarising factor (EDHF) pathway or its main components, the small-conductance Ca(2+) activated potassium (SK(Ca)) and intermediate-conductance Ca(2+) activated potassium (IK(Ca)) channels. In moxifloxacin-treated rats, an increase in the EDHF response was observed, which was largely attributed to SK(Ca)-activation. In conclusion, levofloxacin and moxifloxacin use appeared to vary but with no evidence of impairment of the cardiovascular function. However, it is still possible that these antibiotics may produce different effects if there are co-morbidities and therefore their use must be with care.
authors.affiliation: Pharmacology and Toxicology Department, Aleppo University, Syria. mais.absi@manchester.ac.uk
authors.forename: Mais
authors.initials: M
authors.lastname: Absi
authors.forename: Hussam
authors.initials: H
authors.lastname: Ghareeb
authors.forename: Ahmad
authors.initials: A
authors.lastname: Khalil
authors.forename: Urs T
authors.initials: UT
authors.lastname: Ruegg
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D001685:Biological Factors; D001786:Blood Glucose / Q000187:drug effects; D001919:Bradycardia / Q000139:chemically induced; D002319:Cardiovascular System / Q000187:drug effects*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000503:physiopathology*; D004562:Electrocardiography; D004730:Endothelium, Vascular / Q000187:drug effects; D024841:Fluoroquinolones / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007003:Hypoglycemia / Q000139:chemically induced*; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels / Q000187:drug effects; D064704:Levofloxacin; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D051640:Small-Conductance Calcium-Activated Potassium Channels / Q000187:drug effects; D013311:Streptozocin
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D001685:Biological Factors; D001786:Blood Glucose; D024841:Fluoroquinolones; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; D011804:Quinolines; D051640:Small-Conductance Calcium-Activated Potassium Channels; C067410:endothelium-dependent hyperpolarization factor; D013311:Streptozocin; D064704:Levofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin